Intellia Therapeutics, Inc. (NTLA)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch NTLA
See up to 3 months of NTLA. The 7-day demo opens the 1M and 3M ranges and puts NTLA on your watchlist.
Start 7-day demoLatest NTLA insider trades
Michael P. Dube - OfficerOpen-market sale$23K
About Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. is an SEC registrant, filing under CIK 0001652130, classified as in vitro and in vivo diagnostic substances. We track it alongside the rest of the Health Care sector.
NTLA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 32,650 | $401K |
NTLA insider transactions (Form 4)
5236 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 1 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael P. Dube - Officer | Open-market sale | Common Stock | 1,864 | $12.43 | $23K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 19,890 | $12.60 footnote F2 | $251K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 2,785 | $13.00 | $36K | |
| ||||||
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 8,111 | $11.25 footnote F2 | $91K | |
| ||||||
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,641 | $16.78 footnote F2 | $44K | |
| ||||||
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 4,677 | $18.00 | $84K | |
 Frank Verwiel | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Frank Verwiel | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Georgia Keresty | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Georgia Keresty | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| Jesse Goodman | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Jesse Goodman | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Brian Goff | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Brian Goff | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| Fred E. Cohen | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Fred E. Cohen | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 William J. Chase | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| William J. Chase | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Muna Bhanji | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Muna Bhanji | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| John M. Leonard - Officer | Grant or award | Common Stock | 156,400 | $0.00 | - | |
| John M. Leonard - Officer | Grant or award | Stock Option (right to buy) | 225,400 | $0.00 | - | |
 James Basta - Officer | Grant or award | Common Stock | 46,080 | $0.00 | - | |
| James Basta - Officer | Open-market sale | Common Stock | 1,211 | $13.78 | $17K | |
| James Basta - Officer | Grant or award | Stock Option (right to buy) | 65,829 | $0.00 | - | |
| David Lebwohl - Officer | Grant or award | Stock Option (right to buy) | 14,204 | $0.00 | - | |
| David Lebwohl - Officer | Grant or award | Common Stock | 9,943 | $0.00 | - | |
| Edward J. Dulac III - Officer | Grant or award | Common Stock | 61,280 | $0.00 | - | |
| Edward J. Dulac III - Officer | Grant or award | Stock Option (right to buy) | 87,543 | $0.00 | - | |
| Birgit C. Schultes - Officer | Grant or award | Common Stock | 39,200 | $0.00 | - | |
| Birgit C. Schultes - Officer | Grant or award | Stock Option (right to buy) | 56,000 | $0.00 | - | |
| Eliana Clark - Officer | Grant or award | Common Stock | 7,353 | $0.00 | - | |
| Eliana Clark - Officer | Open-market sale | Common Stock | 607 | $13.78 | $8K | |
| Eliana Clark - Officer | Grant or award | Stock Option (right to buy) | 10,505 | $0.00 | - | |
| Michael P. Dube - Officer | Grant or award | Common Stock | 17,250 | $0.00 | - | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 34,146 | $9.21 | $314K | |
| Birgit C. Schultes - Officer | Open-market sale | Common Stock | 8,508 | $9.21 | $78K | |
| James Basta - Officer | Open-market sale | Common Stock | 10,397 | $9.21 | $96K | |
| Fred E. Cohen | Open-market purchase | Common Stock | 150,000 | $9.35 | $1.40M | |
| David Lebwohl - Officer | Open-market sale | Common Stock | 11,903 | $9.21 | $110K | |
| Eliana Clark - Officer | Open-market sale | Common Stock | 9,515 | $9.21 | $88K | |
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 6,379 | $9.21 | $59K | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,989 | $9.21 | $28K | |
| John M. Leonard - Officer | Option exercise | Common Stock | 49,959 | $6.83 | $341K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 49,959 | $9.49 footnote F2 | $474K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 32,832 | $9.47 footnote F3 | $311K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 5,355 | $9.59 footnote F4 | $51K | |
| John M. Leonard - Officer | Option exercise | Common Stock | 8,557 | $6.83 | $58K | |
| John M. Leonard - Officer | Option exercise | Stock Option (right to buy) | 49,959 | $0.00 | - | |
| John M. Leonard - Officer | Option exercise | Stock Option (right to buy) | 8,557 | $0.00 | - | |
| ||||||
| Birgit C. Schultes - Officer | Open-market sale | Common Stock | 31 | $17.38 | $539 | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 1,871 | $17.38 | $33K | |
Item 7.01, 8.01, 9.01
Item 1.01, 2.03, 7.01, 9.01
Item 2.02, 9.01
Item 7.01, 8.01, 9.01
Recent NTLA Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Eliana Clark | Officer | 57,750 | $736K | View on EDGAR | |
| John M. Leonard | Officer, Director | 22,675 |
NTLA insider trading FAQ
What is the latest insider trade for NTLA?
Intellia Therapeutics, Inc. (NTLA) had 3 insider filings in the last 90 days, with the most recent on 6 October 2026. The full record for NTLA runs to 36 Form 4 filings, the earliest from 4 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NTLA stock?
No insider purchases of NTLA were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling NTLA stock?
4 insider sales of NTLA were filed in the last 90 days, totaling $401K.
Where can I see NTLA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NTLA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael P. Dube view on EDGAR
- - John M. Leonard view on EDGAR
- - Edward J. Dulac III view on EDGAR
- - Michael P. Dube view on EDGAR
- - Edward J. Dulac III view on EDGAR
- - Frank Verwiel view on EDGAR
- - Georgia Keresty view on EDGAR
- - Jesse Goodman view on EDGAR
- - Brian Goff view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NTLA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NTLA with a 7-day demo
- NTLA on your watchlist
- Every NTLA Form 4 filing on record
- Up to 3 months of NTLA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
